Medical Care Technologies Inc. Unveils Breakthrough AI for Early Melanoma Detection
Medical Care Technologies (OTC:MDCE) has unveiled a groundbreaking AI platform for early melanoma detection. The technology leverages deep learning algorithms trained on millions of dermatoscopic and clinical images to analyze key melanoma risk factors including asymmetry, border irregularities, color variations, diameter, and evolution monitoring.
The AI system creates longitudinal profiles of moles and lesions, flagging anomalies before progression. This advancement is particularly significant as melanoma, while representing only 1% of skin cancers, causes the majority of skin cancer deaths. When detected early, melanoma survival rates exceed 95%.
Medical Care Technologies (OTC:MDCE) ha svelato una piattaforma IA rivoluzionaria per il rilevamento precoce del melanoma. La tecnologia utilizza algoritmi di deep learning addestrati su milioni di immagini dermatoscopiche e cliniche per analizzare i principali fattori di rischio del melanoma, tra cui asimmetria, bordi irregolari, variazioni di colore, diametro e monitoraggio dell'evoluzione. Il sistema IA crea profili longitudinali di nei e lesioni, segnalando anomalie prima della progressione. Questo progresso è particolarmente significativo poiché il melanoma, pur rappresentando solo 1% dei tumori della pelle, provoca la maggior parte dei decessi per tumore della pelle. Quando rilevato precocemente, la sopravvivenza al melanoma supera il 95%.
Medical Care Technologies (OTC:MDCE) ha presentado una plataforma de IA revolucionaria para la detección temprana del melanoma. La tecnología utiliza algoritmos de aprendizaje profundo entrenados con millones de imágenes dermatoscópicas y clínicas para analizar los principales factores de riesgo del melanoma, como asimetría, irregularidad de bordes, variaciones de color, diámetro y monitorización de la evolución. El sistema de IA crea perfiles longitudinales de lunares y lesiones, señalando anomalías antes de que progresen. Este avance es especialmente significativo porque el melanoma, si bien representa solo el 1% de los cánceres de piel, es la principal causa de muertes por cáncer de piel. Cuando se detecta temprano, la supervivencia del melanoma supera el 95%.
Medical Care Technologies (OTC:MDCE)가 초기 흑색종 탐지를 위한 혁신적인 AI 플랫폼을 공개했습니다. 이 기술은 수백만 장의 피부진단 이미지와 임상 이미지를 바탕으로 심미성, 경계 불규칙성, 색 변이, 직경 및 변화를 모니터링하는 등 흑색종의 주요 위험 요인을 분석합니다. AI 시스템은 점이나 병변의 종단적 프로필을 생성하고 진행 전에 이상 신호를 표시합니다. 이 진전은 특히 흑색종이 피부암의 1%에 불과하더라도 피부암 사망의 대부분을 차지한다는 점에서 중요합니다. 조기 발견 시 흑색종 생존율은 95%를 넘습니다.
Medical Care Technologies (OTC:MDCE) a dévoilé une plateforme IA révolutionnaire pour la détection précoce du mélanome. La technologie s’appuie sur des algorithmes d’apprentissage profond entraînés sur des millions d’images dermatoscopiques et cliniques afin d’analyser les principaux facteurs de risque du mélanome, tels que l’asymétrie, les bords irréguliers, les variations de couleur, le diamètre et le suivi de l’évolution. Le système IA crée des profils longitudinaux de grains de beauté et de lésions, en signalant les anomalies avant toute progression. Cette avancée est particulièrement significative car le mélanome, bien qu’il représente seulement 1% des cancers de la peau, cause la majorité des décès par cancer de la peau. Lorsqu’il est détecté tôt, le taux de survie au mélanome dépasse 95%.
Medical Care Technologies (OTC:MDCE) hat eine wegweisende KI-Plattform zur frühen Melanom-Erkennung vorgestellt. Die Technologie nutzt Deep-Learning-Algorithmen, die mit Millionen von dermatoskopischen und klinischen Bildern trainiert wurden, um zentrale Melanom-Risikofaktoren wie Asymmetrie, unregelmäßige Ränder, Farbvariationen, Durchmesser und Evolutionsmonitoring zu analysieren. Das KI-System erstellt longitudinale Profile von Muttermalen und Läsionen und kennzeichnet Auffälligkeiten, bevor sie fortschreiten. Dieser Fortschritt ist besonders bedeutsam, da Melanom zwar nur 1% der Hautkrebsfälle ausmacht, jedoch die Mehrheit der Hautkrebs-Todesfälle verursacht. Bei frühzeitiger Erkennung liegen die Überlebensraten beim Melanom bei über 95%.
Medical Care Technologies (OTC:MDCE) أعلنت عن منصة ذكاء اصطناعي رائدة للكشف المبكر عن الورم الميلانيني. تعتمد التقنية على خوارزميات تعلم عميق مُدربة على ملايين الصور الجلدية بالتصوير dermatoscopic والصور السريرية لتحليل عوامل الخطر الرئيسية للميلانوما بما في ذلك عدم التماثل، وعدم انتظام الحواف، وتفاوت اللون، القطر، ومراقبة التطور. تنشئ منصة الذكاء الاصطناعي ملفات طولية للعلامات والبقع وتعلّم الإشارة إلى الشذوذ قبل تطورها. هذا التقدم مهم بشكل خاص، فالميلانوما، رغم أنه يمثل 1% من سرطان الجلد، يسبب غالبية وفيات سرطان الجلد. عندما يتم الكشف المبكر، تتجاوز معدلات البقاء على قيد الحياة للميلانوما 95%.
Medical Care Technologies (OTC:MDCE) 已推出用于早期黑色素瘤检测的突破性人工智能平台。该技术利用在数百万张 dermatoscopic 及临床图像上训练的深度学习算法，分析黑色素瘤的主要风险因素，包括不对称、边界不规则、颜色变化、直径和演变监测。该 AI 系统能创建痣和病变的纵向档案，在进展前标记异常。此项进展尤为重要，因为黑色素瘤仅占皮肤癌的 1%，但造成皮肤癌死亡的多数。当及早发现时，黑色素瘤的存活率超过 95%。
- AI platform enables early detection of melanoma before clinical obviousness
- Technology leverages deep learning trained on millions of dermatoscopic images
- System provides longitudinal monitoring and automated anomaly detection
- Solution brings professional-grade diagnostic capabilities into home settings
- Technology is still new and unproven in real-world settings
- No regulatory approval status mentioned in the announcement
MESA, ARIZONA / ACCESS Newswire / September 18, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a leader in AI-powered preventive healthcare, today announced a major advancement in dermatology: an artificial intelligence platform designed to revolutionize the early detection of melanoma, the deadliest form of skin cancer.
Melanoma accounts for only
How the Technology Works
The system leverages deep learning algorithms trained on millions of dermatoscopic and clinical images to analyze key melanoma risk factors:
Asymmetry in lesion structure
Border irregularities at the cellular level
Color variegation, including detection of subtle pigment changes invisible to the human eye
Diameter tracking over time
Evolution monitoring, comparing each lesion against a patient's personal historical baseline
By building a longitudinal profile of every mole and lesion, the AI flags anomalies and recommends triage before progression, transforming skin self-checks into a powerful early warning system.
"Melanoma's danger lies in its ability to grow undetected until it's too late," said Marshall Perkins, CEO of MDCE. "Our AI technology brings an AI powered diagnostic tool into the home, empowering patients and clinicians with earlier, more precise insights that can save lives."
About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTC: MDCE) is committed to advancing AI-driven preventive healthcare, from mental health and neurological monitoring to dermatological and ocular disease detection.
Company Websites: www.medicalcaretechnologies.com | www.mdcestock.com
Forward-Looking Statements: This press release contains forward-looking statements within the meaning of federal securities laws. Actual results may differ materially.
Contact:
Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com
SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)
View the original press release on ACCESS Newswire
FAQ
What is Medical Care Technologies' (MDCE) new AI melanoma detection technology?
How effective is early melanoma detection for survival rates?
What features does MDCE's AI melanoma detection system analyze?
How does MDCE's AI melanoma detection platform work?
Who is leading Medical Care Technologies' AI melanoma detection initiative?
